
Urogen Pharma Ltd UR8.F:
UROGEN ANNOUNCES FDA ADVISORY COMMITTEE FOR UGN-102, AN INVESTIGATIONAL TREATMENT FOR RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER
UROGEN PHARMA LTD - FDA SCHEDULES ODAC MEETING FOR UROGEN'S UGN-102 ON MAY 21, 2025
UROGEN PHARMA LTD - FDA TARGETS JUNE 13, 2025 FOR UGN-102 REVIEW COMPLETION